About this item:

617 Views | 1,007 Downloads

Author Notes:

E-mail: biozrl@langate.gsu.edu (ZL); chejjy@langate.gsu.edu (JJY)

For author contributions and acknowledgments, see the full article.

The authors have declared that no competing interests exist.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


Research Funding:

This work is supported in part by research grants from NIH CA118113 to Zhi-Ren Liu, NIH GM62999 and EB007268 to Jenny J Yang, and Georgia State University Brain and Behavior fellowship to Jingjuan Qiao.


  • Science & Technology
  • Multidisciplinary Sciences
  • Magnetic resonance imaging
  • Near-infrared spectroscopy
  • Cancer treatment
  • Cell binding assay
  • Immunostaining
  • In vivo imaging
  • NMR relaxation
  • Mouse models

HER2 Targeted Molecular MR Imaging Using a De Novo Designed Protein Contrast Agent

Show all authors Show less authors


Journal Title:



Volume 6, Number 3


, Pages e18103-e18103

Type of Work:

Article | Final Publisher PDF


The application of magnetic resonance imaging (MRI) to non-invasively assess disease biomarkers has been hampered by the lack of desired contrast agents with high relaxivity, targeting capability, and optimized pharmacokinetics. We have developed a novel MR imaging probe targeting to HER2, a biomarker for various cancer types and a drug target for anti-cancer therapies. This multimodal HER20targeted MR imaging probe integrates a de novo designed protein contrast agent with a high affinity HER2 affibody and a near IR fluorescent dye. Our probe can differentially monitor tumors with different expression levels of HER2 in both human cell lines and xenograft mice models. In addition to its 100-fold higher dose efficiency compared to clinically approved non-targeting contrast agent DTPA, our developed agent also exhibits advantages in crossing the endothelial boundary, tissue distribution, and tumor tissue retention over reported contrast agents as demonstrated by even distribution of the imaging probe across the entire tumor mass. This contrast agent will provide a powerful tool for quantitative assessment of molecular markers, and improved resolution for diagnosis, prognosis and drug discovery.

Copyright information:

© 2011 Qiao et al.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote